Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evofosfamide - ImmunoGenesis

Next Previous
Drug Profile

Evofosfamide - ImmunoGenesis

Alternative Names: HAP 302; IMGS-101; TH-302; TH302-cpd

Latest Information Update: 03 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Threshold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer Grupo Espanol de Tumores Neuroendocrinos; IMMUNOGENESIS; Merck KGaA; Molecular Templates; Threshold Pharmaceuticals; University of Texas Health Science Center at San Antonio; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitroimidazoles; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Glioblastoma
  • Phase I/II Prostate cancer; Squamous cell cancer
  • Suspended Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Discontinued Soft tissue sarcoma

Most Recent Events

  • 20 Feb 2025 University Health Network and ImmunoGenesis plans a phase II trial for Prostate cancer (Second-line therapy or greater, Hormone refractory) in Canada (IV) (NCT06836726)
  • 08 Jan 2025 Phase-I/II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (IV) (NCT06782555)
  • 08 Jan 2025 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease, Hormone refractory) in USA (IV) (NCT06782555)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top